New concession of the Seal of Excellence by the European Union
VIVEbiotech has been awarded again with the Seal of Excellence by the European Union with the project entitled “Safeguarding gene therapy: LENTISOMA an innovative safEfficient vehicle for medicinal genes”.
Following evaluation by an international panel of independent experts, the Project was scored as a high-quality project proposal in a highly competitive evaluation process. The Lentisoma project consists of an episomal non-integrative stable lentiviral vector that provides the lasting, stable and consistent expression of the transgene in dividing and non-dividing cells.
This is recognition of the work carried out by VIVEbiotech, a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors.
